Anzeigenschluss: 10.04.2025
Erscheinungstermin: 28.04.2025
Top-Thema
Zelluläre Therapien mit NK-Zellen (CAR, BiTE, ICI etc.)
Schwerpunkt: State of the Art TNBC: Was, wann und warum? Subtypisierung für eine bessere zielgerichtete Therapie
Therapieoptimierung beim TNBC
Fan L et al.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Resistenzentwicklung beim TNBC
Ning B et al.
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer.
PI3K-Signalwegalterationen beim TNBC
Basho RK et al.
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Präzisionsmedizin durch Subtypisierung beim TNBC
Jézéquel P et al.
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
Medizin
Multiples Myelom
Facon T et al.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
AML
Sobas MA et al.
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Kopf-Hals-Tumoren
Villa A et al.
Oncological Outcomes of Patients With Oral Potentially Malignant Disorders.
Darmkrebs
Papier K et al.
Diet-wide analyses for risk of colorectal cancer: prospective study of 12,251 incident cases among 542,778 women in the UK.
Leberkrebs
Kudo M et al.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Brustkrebs
Jhaveri KL et al.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Brustkrebs
Mosher CE et al.
Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer.
Ovarialkarzinom
Mah SJ et al.
Timing of Palliative Care, End-of-Life Quality Indicators, and Health Resource Utilization.
Brustkrebs
Honoré A et al.
Concordance with final pathology when transitioning from standard transrectal to cognitive targeted transperineal prostate biopsy.
Prostatakarzinom
Hamm CA et al.
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.
Hautkrebs
Wolchok JD et al.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Allgemeine Onkologie
Urquhart R et al.
Fear of cancer recurrence is associated with higher primary care use after cancer treatment: a survey-administrative health data linkage study.
Kongressbericht 1: ELCC 2025
Neues European Lung Cancer Congress (ELCC 2025) vom 26.-29.03.2025 in Paris, Frankreich
Kongressbericht 2: DGHO-Frühjahrstagung 2025
Aktuelles von der DGHO-Frühjahrstagung am 14.3.2025 in Berlin
Kongressbericht 3: ISAL XVIV
Highlights vom 19th International Symposium ACUTE LEUKEMIAS (ISAL XVIV) in München vom 16.-19.03.2025
*Die Redaktion behält sich aktuelle Änderungen vor.